Researchers

October 29, 2025

The IIS Aragón is organizing an informative workshop on the role of protein in cardiovascular health

The activity is driven by the Primary Dyslipidemias research group of the IIS Aragón, led by professors and researchers from the Institute and the University of Zaragoza.
October 28, 2025

Javier Marta, neurologist: "I became interested in neuroscience after reading about how 'ET' was made."

We share the following interview from Heraldo de Aragón with the head of the Stroke Unit at Servet Hospital, clinical coordinator of the Aragon Stroke Plan and head of the Neuroscience Research Group at IIS Aragón.
October 23, 2025

The IIS Aragón advances in its HRS4R certification with the visit of the European audit team.

The event marks a decisive step in the HR Excellence in Research certification process, which recognizes the IIS Aragón's commitment to continuously improving the working conditions of research staff in line with European policies.
11 June, 2025

The Mediterranean diet may act as a protective factor against the genetic risk of obesity in European preadolescents.

This is demonstrated by a study led by the GENUD group (IIS Aragón and the University of Zaragoza), which has just been published in the journal Pediatric Obesity with an analysis of 2000 participants, between 2 and 16 years old, over three different years.
10 June, 2025

A new species of mycobacterium has been discovered at the Miguel Servet University Hospital in Zaragoza.

Professionals from HUMS and IIS Aragón, among other institutions, participated in the research. The bacteria has been named "Mycobacterium servetii" in honor of the Renaissance physician and the hospital.
8 May 2025

Aspanoa invests 120.000 euros to promote new immunotherapies for childhood cancer.

It will be distributed equally between two research projects. One is led by Diego Sánchez (IIS Aragón) and the other by Eva Gálvez (CSIC) and Ramón Hurtado (BIFI – Unizar). Immunotherapy is a treatment already being applied to some cancer patients, including children, when standard therapies are insufficient.
6 May 2025

A new experimental drug improves motor function and prolongs life in an ALS model.

The MP-010 molecule, developed by Miramoon Pharma, acts on ryanodine receptors, opening a new therapeutic avenue for treating ALS, according to a study led by researchers from CIBERNED and several research institutes, including the IIS Aragón.